Abstract
This thorough analysis looks critically at how glycosaminoglycan (GAG) supports joint health. It emphasizes the importance of GAG in particular, clarifies the underlying processes linked to joint pain, and assesses the shortcomings of traditional therapy modalities. Additionally, the research delves into several traditional approaches, such as injectable GAG therapy and oral supplements, carefully evaluating the benefits and drawbacks of each. The study then explores novel GAG drug delivery technologies, acknowledging the urgent need for better treatment approaches. The article highlights the potential of hydrogel-based systems, liposomal/micellar carriers, and nanoparticles in addressing current challenges in GAG delivery. These challenges include achieving sustained release, improving bioavailability, facilitating targeted delivery, and reducing safety concerns related to biocompatibility. Examining these elements closely and critically, the review seeks to provide a thorough grasp of the developments, difficulties, and possible breakthroughs in GAG delivery systems. In the end, this thorough investigation will greatly aid in the improvement of joint pain therapies. The results imply that by shielding articular joints from erosive effects, early use of GAG therapy-particularly hyaluronic acid-can reduce joint deterioration associated with arthritis. Even though GAG-based therapies have shown promise in lowering inflammation and increasing joint flexibility, further study is required to improve their effectiveness in treating joint pain, particularly in diseases like osteoarthritis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call